Skip to main content
Top
Published in: BMC Infectious Diseases 1/2018

Open Access 01-12-2018 | Research article

High heterogeneity in community-acquired pneumonia inclusion criteria: does this impact on the validity of the results of randomized controlled trials?

Authors: Clara Flateau, Josselin Le Bel, Sarah Tubiana, François-Xavier Blanc, Christophe Choquet, Blandine Rammaert, Patrick Ray, Christophe Rapp, Cécile Ficko, Catherine Leport, Yann-Erick Claessens, Xavier Duval, on behalf of the ESCAPED study group

Published in: BMC Infectious Diseases | Issue 1/2018

Login to get access

Abstract

Background

There is no consensus on the most accurate combination of diagnostic criteria to define community acquired pneumonia (CAP). We describe inclusion criteria in randomized controlled trials (RCT) of CAP and assess their performance for the diagnosis of formally identified CAP.

Methods

RCTs related to CAP recorded on ClinicalTrials.gov were analysed. Due to high heterogeneity, we divided close CAP inclusion criteria into patterns (i.e. combinations of inclusion criteria). To assess their diagnostic performances, these CAP definition patterns were applied to a reference population of 319 suspected CAP patients, in whom the CAP diagnosis had been confirmed (n = 163) or excluded (n = 156) by an adjudication committee after a systematic thoracic CT-scan and a 28-day follow-up period.

Results

In the 47 RCTs included in the analysis, 42 different CAP inclusion criteria combinations were identified and 8 patterns created. This heterogeneity was not explained either by the trials’ methodology or by their objectives. When applied to the reference population, the performance ranges of the 8 definition patterns were 9.8–56.4% for sensitivities, 56.4 97.4% for specificities, 63.6 83.6% for positive predictive values and 50.8–66.7% for negative predictive values. None of the CAP definitions had both sensitivity and specificity superior to 65%. Depending on the CAP definition, the rate of included patients without CAP (“false positives”) ranged from 1 to 21%.

Conclusions

CAP diagnostic criteria within RCTs are heterogeneous, which may have far-reaching consequences on validity of RCT results.
Literature
2.
go back to reference Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. N Engl J Med. 2014;370:543–51.CrossRefPubMed Wunderink RG, Waterer GW. Clinical practice. Community-acquired pneumonia. N Engl J Med. 2014;370:543–51.CrossRefPubMed
3.
go back to reference Ruiz-Gonzalez A, Falguera M, Nogues A, Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology ? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med. 1999;106:385–90.CrossRefPubMed Ruiz-Gonzalez A, Falguera M, Nogues A, Rubio-Caballero M. Is Streptococcus pneumoniae the leading cause of pneumonia of unknown etiology ? A microbiologic study of lung aspirates in consecutive patients with community-acquired pneumonia. Am J Med. 1999;106:385–90.CrossRefPubMed
4.
go back to reference Claessens Y-E, Debray M-P, Tubach F, Brun AL, Rammaert B, Hausfater P, et al. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am J Respir Crit Care Med. 2015;192:974–82.CrossRefPubMed Claessens Y-E, Debray M-P, Tubach F, Brun AL, Rammaert B, Hausfater P, et al. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am J Respir Crit Care Med. 2015;192:974–82.CrossRefPubMed
5.
go back to reference Upchurch CP, Grijalva CG, Wunderink RG, Williams DJ, Waterer GW, Anderson EJ, et al. Community-acquired pneumonia visualized on CT scans but not chest radiographs: pathogens, severity, and clinical outcomes. Chest. 2018;153(3):601–10.CrossRefPubMed Upchurch CP, Grijalva CG, Wunderink RG, Williams DJ, Waterer GW, Anderson EJ, et al. Community-acquired pneumonia visualized on CT scans but not chest radiographs: pathogens, severity, and clinical outcomes. Chest. 2018;153(3):601–10.CrossRefPubMed
6.
go back to reference Prendki V, Scheffler M, Huttner B, Garin N, Herrmann F, Janssens JP, et al. Low-dose CT for the diagnosis of pneumonia in elderly patients: a prospective, interventional cohort study. Eur Respir J. 2018;12 [Epub ahead of print]. Prendki V, Scheffler M, Huttner B, Garin N, Herrmann F, Janssens JP, et al. Low-dose CT for the diagnosis of pneumonia in elderly patients: a prospective, interventional cohort study. Eur Respir J. 2018;12 [Epub ahead of print].
7.
go back to reference Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl):1–55. Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl):1–55.
8.
go back to reference National Clinical Guideline Centre (UK). Pneumonia: diagnosis and management of community- and hospital-acquired pneumonia in adults. London: National Institute for Health and Care Excellence (UK); 2014. National Clinical Guideline Centre (UK). Pneumonia: diagnosis and management of community- and hospital-acquired pneumonia in adults. London: National Institute for Health and Care Excellence (UK); 2014.
9.
go back to reference Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Guidelines for the management of adult lower respiratory tract infections. Full version. Clin Microbiol Infect. 2011;17(Suppl 6):1–59.CrossRefPubMed Woodhead M, Blasi F, Ewig S, Garau J, Huchon G, Ieven M, et al. Guidelines for the management of adult lower respiratory tract infections. Full version. Clin Microbiol Infect. 2011;17(Suppl 6):1–59.CrossRefPubMed
10.
go back to reference Infectious Diseases Society of America (IDSA), American College of Chest Physicians (ACCP), American Thoracic Society (ATS), et al. Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51(Suppl 1):150–70. Infectious Diseases Society of America (IDSA), American College of Chest Physicians (ACCP), American Thoracic Society (ATS), et al. Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51(Suppl 1):150–70.
11.
go back to reference Oczkowski SJW. A clinician’s guide to the assessment and interpretation of noninferiority trials for novel therapies. Open Med. 2014;8:67–72. Oczkowski SJW. A clinician’s guide to the assessment and interpretation of noninferiority trials for novel therapies. Open Med. 2014;8:67–72.
12.
go back to reference Mulla SM, Scott IA, Jackevicius CA, You JJ, Guyatt GH. How to use a noninferiority trial: users’ guides to the medical literature. JAMA. 2012;308:2605–11.CrossRefPubMed Mulla SM, Scott IA, Jackevicius CA, You JJ, Guyatt GH. How to use a noninferiority trial: users’ guides to the medical literature. JAMA. 2012;308:2605–11.CrossRefPubMed
13.
go back to reference Mandell LA, Waterer GW. Empirical therapy of community-acquired pneumonia: advancing evidence or just more doubt? JAMA. 2015;314:396–7.CrossRefPubMed Mandell LA, Waterer GW. Empirical therapy of community-acquired pneumonia: advancing evidence or just more doubt? JAMA. 2015;314:396–7.CrossRefPubMed
Metadata
Title
High heterogeneity in community-acquired pneumonia inclusion criteria: does this impact on the validity of the results of randomized controlled trials?
Authors
Clara Flateau
Josselin Le Bel
Sarah Tubiana
François-Xavier Blanc
Christophe Choquet
Blandine Rammaert
Patrick Ray
Christophe Rapp
Cécile Ficko
Catherine Leport
Yann-Erick Claessens
Xavier Duval
on behalf of the ESCAPED study group
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Infectious Diseases / Issue 1/2018
Electronic ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-018-3515-9

Other articles of this Issue 1/2018

BMC Infectious Diseases 1/2018 Go to the issue